Dr Lal PathLabs to Acquire 70% Stake in Gujarat-based SN Genelab for INR 168 Cr

The acquisition is aimed at strengthening the diagnostic chain’s capabilities in genomics and expanding its portfolio of advanced diagnostic services.

Leading diagnostic service provider Dr Lal PathLabs is set to acquire a 70% stake in Gujarat-based SN Genelab (SN Gene) for a cash consideration of up to INR 168 crore, according to a regulatory filing by the diagnostics company.

The proposed transaction also includes a performance-linked earn-out capped at INR 31.5 crore.

As per reports, the acquisition will be made from the existing shareholders of SN Gene, following which the genomics company will become a subsidiary of Dr Lal PathLabs.

The transaction is expected to be completed by November 30, 2026.

According to Lal Pathlabs, the acquisition is aimed at strengthening the diagnostic chain’s capabilities in genomics and expanding its portfolio of advanced diagnostic services.

Incorporated on December 16, 2013, Gujarat-based S N Gene operates in the diagnostics-genomics segment, providing genomics diagnostic services.

The company reported a turnover of INR 57.96 crore in FY2026, compared with INR 53.36 crore in FY2025 and INR 43.27 crore in FY2024.

Dr Lal PathLabs said the proposed acquisition does not fall within the ambit of a related-party transaction.

By acquiring a majority stake in SN Gene, Dr Lal PathLabs will gain control over an existing genomics-focused business while adding its capabilities to the company's broader diagnostic network.

The transaction is also intended to provide an avenue for Dr Lal PathLabs to expand its advanced testing portfolio beyond conventional diagnostic services.

Founded in 1949, Dr Lal PathLabs is among India's largest diagnostic service providers, operating an extensive network of laboratories and patient service centres across the country

The acquisition comes as Dr Lal PathLabs continues to expand its diagnostic operations and explore opportunities in international markets.

Recently, Dr Lal PathLabs established a wholly owned subsidiary in Dubai, UAE, as part of its international growth strategy, with plans to pursue acquisitions, partnerships, and investments in diagnostics and allied healthcare services.

The UAE subsidiary will operate in the diagnostics sector and serve as a vehicle for strategic investments in healthcare-related businesses.

Its mandate includes evaluating acquisition opportunities, forming joint ventures, and developing partnerships that could support future growth in international markets.

Stay tuned for more such updates on Digital Health News